|
|
|
| Screening of functional modules and key genes in the progression of Henoch-Schonlein purpura nephritis in children |
| Zhang Qi, Sun Lin, Liu Meina |
| Department of Biostatistics, Harbin Medical University, Harbin 150081, China |
|
|
|
|
Abstract Objective To construct the co-expression network Henoch-Schonlein purpura nephritis (HSPN) of children to screen the functional modules and key genes that related with the progression of HSPN, so as to explore the safe and non-invasive biomarkers of renal injury for the diagnosis, treatment and prognosis of HSPN. Methods We analyzed the correlations between clinical indicators and HSPN progression, and screened the differentially expressed genes between HSP and HSPN patients. Network modules related to the clinical indicators were obtained through weighted gene co-expression network analysis, and GO enrichment analysis was performed for genes in these modules. Key genes were selected according to MM and GS, and their expressions were analyzed in the four progression groups of HSP, HSPN type I, HSPN type II and HSPN type III. Results Hematuria/proteinuria, serum IgA, CRP and C3 were related with the progression of HSPN. Totally 2 399 genes were differentially expressed in HSPN patients, and ten modules were obtained by weighted gene co-expression network analysis, three of which were most relevant to the clinical indicators. Genes in the modules were mainly enriched in the biological processes of immune response mediated by neutrophils, cytokine activity, leukocyte migration, platelet alpha granules and cell adhesion. Eight genes were selected as key genes for the progression of HSPN, namely GPX1-201, INHBA-201, PHLDA1-201, VEGFA-205, CALM2 -201, CDKN2D-202, LDLRAP1-201 and MAP1LC3B-201. Four of them were involved in biological processes such as inflammation and immune response, and cell cycle regulation. Conclusion The three functional modules obtained in this paper affected the clinical indicators related with HSPN progression by participating in biological processes such as inflammation, immune response, and coagulation response; the selected eight key genes were of biological significance and may become the potential biomarkers for progression and kidney injury of HSPN, which might provide guidance and direction for further studying of the HSPN progression mechanism and exploring the potential biomarkers.
|
|
Received: 22 August 2020
|
|
|
|
| ［1］KAWASAKI Y, ONO A, OHARA S, et al. Henoch-Sch-nlein purpura nephritis in childhood: Pathogenesis, prognostic factors and treatment［J］. Fukushima J Med Sci, 2013, 59(1):15-26.
［2］CHEN J Y, MAO J H. Henoch-Sch-nlein purpura nephritis in children: Incidence, pathogenesis and management［J］. World J Pediatr, 2015, 11(1):29-34.
［3］POHL M. HenochSchnlein purpura nephritis［J］. Pediatr Nephrol, 2015, 30(2):245-252.
［4］YANG Y H, YU H H, CHIANG B L. The diagnosis and classification of Henoch-Sch-nlein purpura: An updated review［J］. Autoimmun Rev, 2014, 13(4-5):355-358.
［5］XIE B, ZHANG W, ZHANG Q, et al. An integrated transcriptomic and proteomic analysis identifies significant novel pathways for henoch-sch-nlein purpura nephritis progression［J］. Biomed Res Int, 2020, 2020:2489175.
［6］SUN L, XIE B, ZHANG Q J, et al. Biomarkers identification by a combined clinical and metabonomics analysis in Henoch-Schonlein purpura nephritis children［J］. Oncotarget, 2017, 8(69):114239-114250.
［7］中华医学会儿科学分会肾脏学组.紫癜性肾炎诊治循证指南:2016［J］.中华儿科杂志，2017， 55（9）：647-651.
［8］LANGFELDER P, HORVATH S. WGCNA: an R package for weighted correlation network analysis ［J］. BMC Bioinformatics, 2008, 9(1):559.
［9］DAVIN J C, COPPO R. HenochSchnlein purpura nephritis in children ［J］. Nat Rev Nephrol, 2014, 10(10):563-573.
［10］陈祥云，邱彩玲，张志玲，等.过敏性紫癜患儿血清CRP、IL-21及TNF-α的水平变化及临床应用价值分析［J］.临床研究，2020，17（7）：56-59.
［11］袁婷婷，张锐锋，商巧雨.紫癜性肾炎患儿血清APN、CysC、OPN 和IgA1水平分析［J］.临床输血与检验，2019，21（6）：623-626.
［12］陈述枚，莫樱.过敏性紫癜肾炎的病因和发病机制［J］.中国实用儿科杂志，2001，16（4）：193-194.
［13］莫樱，陈述枚.紫癜性肾炎的发病机制与病理诊断［J］.中国实用儿科杂志，2006，21（6）：407-411.
［14］JEROTIC D, MATIC M, SUVAKOV S, et al. Association of Nrf2, SOD2 and GPX1 polymorphisms with biomarkers of oxidative distress and survival in endstage renal disease patients［J］. Toxins (Basel), 2019, 11(7):E431.
［15］STEVENS M, OLTEAN S. Modulation of VEGF-A alternative splicing as a novel treatment in chronic kidney disease［J］. Genes (Basel), 2018, 9(2):E98.
［16］TANG Z F, LI C W, KANG B X, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses［J］. Nucleic Acids Res, 2017, 45(W1):W98W102. |
| [1] |
. [J]. journal1, 2018, 25(3): 200-202. |
|
|
|
|
